Mandatory notification of trade

08 May 2025 10:00 CEST

Moss, 8 May 2025

Gentian Diagnostics ASA ("Gentian") has today been notified that the following
transaction has been completed:

Norda ASA has purchased 101,848 shares in Gentian at NOK 51.50 per share.
Following the transaction Norda ASA owns 716,099 shares in Gentian. Norda ASA
owns about 4.64% of the total outstanding shares following the transaction.
Norda ASA will together with the Group of companies Kvantia AS, Obligasjon 2 AS,
Caaby AS, RWD AS, Insr ASA and Victoria India Fund AS following the share
transaction hold in total 3,524,218 shares in Gentian, corresponding to approx.
22.85% of the total outstanding shares.

Christian Åbyholm is Chairman of the Board of Norda ASA and is a Member of the
Board of Directors and primary insider in Gentian.

PCA notification pursuant to the EU Market Abuse Regulation Article 19 is
attached.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article
19 and Euronext Oslo Rule Book II.

For further information, please contact:
Njaal Kind, Group CFO
njaal.kind@gentian.no
+47 91 90 65 25

More information:
Access the news on Oslo Bors NewsWeb site

645715_GENT KRT 1500 Norda mai 2025.pdf